LIB THERAPEUTICS, INC.
BiotechLIB THERAPEUTICS, INC. is a biotechnology company focused on Immunology, Cardiovascular, Dermatology.
LIB THERAPEUTICS, INC. at a Glance
- Fast trial execution (20 months median completion)
LIB THERAPEUTICS, INC.'s Key Drugs
LIB THERAPEUTICS, INC.'s core commercial portfolio centers on LEROCHOL, spanning Immunology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
LIB THERAPEUTICS, INC.'s Recent FDA Approvals
LIB THERAPEUTICS, INC. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
LIB THERAPEUTICS, INC.'s Therapeutic Areas
LIB THERAPEUTICS, INC.'s approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LIB THERAPEUTICS, INC.'s Top Competitors
LIB THERAPEUTICS, INC.'s closest competitors by therapeutic-area and drug-target overlap include BAUSCH, BAUSCH AND LOMB INC, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LIB THERAPEUTICS, INC. Pipeline Snapshot
LIB THERAPEUTICS, INC. has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LEROCHOL leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/7 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-12-12
- Latest
- 2025-12-12
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges